Vorasidenib significantly prolongs progression-free survival (PFS) in patients with grade 2 glioma carrying IDH mutations: the median PFS of the control group was 11.1 months, whereas that of the Vorasidenib group was extended to 27.7 months, with a hazard ratio (HR) of 0.39 [141]. Here, IDH2 is linked to central nervous system cancer.